This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
15.6. References
R. Mahley, B. Nathan, and R. Pitas, Apolipoprotein E: Structure, function, and possible roles in Alzheimer’s disease, Ann NY Acad Sci 777:139–145 (1996).
W. Strittmatter, and A. Roses, Apolipoprotein E and Alzheimer’s disease, Ann Rev Neurosci 19:53–77 (1996).
B. Yankner, Mechanisms of neuronal degeneration in Alzheimer’s disease, Neuron 16:921–932 (1996).
D. Selkoe, Alzheimer’s disease: genes, protein, and therapy, Physiol Rev 81:741–766 (2001).
J. Price, and J. Morris, Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease, Ann Neural 45:358–368 (1999).
J. Hardy, and D. J. Selkoe, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics, Science 297:353–6 (2002).
N. Andreasen, E. Vanmechelen, H. Vanderstichele, P. Davidsson, and K. Blennow, Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment, Acta Neurol Scand Suppl 170(Suppl. 179):47–51 (2003).
T. Sunderland, G. Linker, N. Mirza, et al., Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA 289:2094–103 (2003).
K. Hirai, G. Aliev, A. Nunomura, et al., Mitochondrial abnormalities in Alzheimer’s disease, J Neurosci 21:3017–23 (2001).
R. Mahley, and S. Rall, Jr, Apolipoprotein E: Far more than a lipid transport protein, Annu Rev Genomics Hum Genet 1:507–37 (2000).
D. J. Selkoe, Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease, J Clin Invest 110:1375–81 (2002).
B. Schwiegelshohn, J. Presley, M. Gorecki, et al., Effects of apoprotein E on intracellular metabolism of model triglyceride-rich particles are distinct from effects on cell particle uptake, J Biol Chem 270:1761–1769 (1995).
R. Pitas, J. Boyles, S. Lee, D. Foss, and R. Mahley, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins, Biochim Biophys Acta 917:148–161 (1987).
S. Han, G. Einstein, K. Weisgraber, et al., Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study, J Neuropathol Exp Neurol 53:535–544 (1994).
R. DeMattos, L. Curtiss, and D. Williams, A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins, J Biol Chem 273:4206–4212 (1998).
W. Pedersen, S. Chan, and M. Mattson, A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal, J Neurochem 74:1426–1433 (2000).
T. Tokuda, M. Calero, E. Matsubara, et al., Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides, Biochem J 348:358–365 (2000).
L. Myllykangas, T. Polvikoski, K. Reunanen, et al., ApoE epsilon3-haplotype modulates Alzheimer beta-amyloid deposition in the brain, Am J Med Genet 114:288–291 (2002).
D. Mauch, K. Nagler, S. Schumacher, et al., CNS synaptogenesis promoted by gliaderived cholesterol, Science 294:1354–1357 (2001).
N. Bogdanovic, L. Bretillon, E. Lund, et al., On the turnover of brain cholesterol in patients with Alzheimer’s disease: Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells, Neurosci Lett 314:45–48 (2001B).
A. Cedazo-Minguez, and R. Cowburn, Apolipoprotein E isoform-specific disruption of phosphoinositide hydrolysis: protection by estrogen and glutathione, FEBS Lett 504:45–49 (2001).
Y. Hashimoto, H. Jiang, T. Niikura, et al., Neuronal apoptosis by apoplipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases, J Neurosci 20:8401–8409 (2000).
D. Kang, C. Pietrzik, L. Baum, et al., Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway, J Clin Invest 106:1159–1166 (2000).
M. Shibata, S. Yamada, S. Kumar, et al., Clearance of Alzheimer’s amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier, J Clin Invest 106:1489–1499 (2000).
L. Puglielli, R. E. Tanzi, and D. M. Kovacs, Alzheimer’s disease: the cholesterol connection, Nat Neurosci 6:345–51 (2003).
M. Meyer, J. Tschanz, M. Norton, et al., APOE genotype predicts when—not whether—one is predisposed to develop Alzheimer disease, Nature Genet 1199:321–322 (1998).
S. Craft, L. Teri, S. Edland, et al., Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease, Neurology 51:149–53 (1998B).
E. Reiman, R. Caselli, L. Yun, et al., Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E, New Engl J Med 334:752–8 (1996).
E. Reiman, R. Caselli, K. Chen, G. Alexander, D. Bandy, and J. Frost, Declining brain activity in cognitively normal apolipoprotein E epsilon4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease, Proc Natl Acad Sci USA 98:3334–3339 (2001).
N. R. Graff-Radford, R. C. Green, R. C. Go, et al., Association between apolipoprotein E genotype and Alzheimer disease in African American subjects, Arch Neurol 59:594–600 (2002).
P. Greenwood, T. Sunderland, J. Friz, and R. Parasuraman, Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene, Proc Natl Acad Sci USA 97:11661–11666 (2000).
G. Gibson, V. Haroutunian, H. Zhang, et al., Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype, Ann Neurol 48:297–303 (2000).
D. Schmechel, A. Saunders, W. Strittmatter, et al., Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in lateonset Alzheimer disease, Proc Natl Acad Sci USA 90:9649–9653 (1993).
D. Cook, L. JB, P. McMillan, et al., Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-episilon4 allele, American Journal of Pathology 162:313–319 (2003).
E. Corder, K. Robertson, L. Lannfelt, et al., HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy, Nature Med 4:1182–1184 (1998).
B. Tardiff, M. Newman, A. Saunders, et al., Preliminary report of a genetic basis for cognitive decline after cardiac operations: The Neurologic Outcome Research Group of the Duke Heart Center, Ann Thorac Surg 64:715–720 (1997).
B. Jordan, N. Relkin, L. Ravdin, A. Jacobs, A. Bennett, and S. Gandy, Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing, J Am Med Assoc 278:136–140 (1997).
G. Teasdale, J. Nicoll, G. Murray, and M. Fiddes, Association of apolipoprotein E polymorphism with outcome after head injury, Lancet 350:1069–1071 (1997).
D. M. Holtzman, K. R. Bales, T. Tenkova, et al., Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease, Proc Natl Acad Sci U S A 97:2892–7 (2000).
Z. S. Ji, R. D. Miranda, Y. M. Newhouse, K. H. Weisgraber, Y. Huang, and R. W. Mahley, Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells, J Biol Chem 277:21821–8 (2002).
R. Mayeux, A. Saunders, S. Shea, et al., Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease, New Engl J Med 338:506–511 (1998).
G. Small, L. Ercoli, D. Silverman, et al., Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease, Proc Natl Acad Sci USA 97:6037–6042 (2000).
S. Rapoport, Functional brain imaging to identify affected subjects genetically at risk for Alzheimer’s disease, Proc Natl Acad Sci USA 97:5696–5698 (2000).
G. Alexander, K. Chen, P. Pietrini, S. Rapoport, and E. Reiman, Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies, Am J Psychiatry 159:738–745 (2002).
V. Mooser, N. Helbecque, J. Miklossy, S. Marcovina, P. Nicod, and P. Amouyel, Interactions between apolipoprotein E and apolipoprotein(a) in patients with lateonset Alzheimer disease, Annals Internal Med 132:533–537 (2000).
L. Fairer, L. Cupples, J. Haines, et al., Effects of age sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A metaanalysis. APOE and Alzheimer Disease Meta Analysis Consortium, J Am Med Assoc 278:1349–1356 (1997).
M. Tang, Y. Stern, K. Marder, et al., The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, Whites and Hispanics, J Am Med Assoc 279:751–755 (1998).
G. Thinakaran, The role of presenilins in Alzheimer’s disease, Journal of Clinical Investigation 104:1321–7 (1999).
O. Murayama, T. Tomita, N. Nihonmatsu, et al., Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer’s disease, Neurosci Lett 265:61–63 (1999).
R. Kopan, and A. Goate, A common enzyme connects notch signaling and Alzheimer’s disease, Genes Devel 14:2799–2806 (2000).
S. Sisodia, and P. St. George-Hyslop, gamma-Secretase, Notch, Abeta and Alzheimer’s disease: where do the presenilins fit in?, Nat Rev Neurosci 3:281–290 (2002).
W. Dowjat, H. Wisniewski, and T. Wisniewski, Alzheimer’s disease presenilin-1 expression modulates the assembly of neurofilaments, Neurosci 103:1–8 (2001).
V. Askanas, W. Engel, C.-C. Yang, R. Alvarez, V.-Y. Lee, and T. Wisniewski, Light and electron microscopic immunolocalization of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy, Am J Pathol 152:889–895 (1998A).
V. Askanas, and W. Engel, Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer’s disease? Clues from inclusion body myositis cultured human muscle and transgenic mice, Am J Path 153:1673–1677 (1998B).
G. Vattemi, W. Engel, J. McFerrin, J. Buxbaum, L. Pastorino, and V. Askanas, Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusionbody myositis, Lancet 358:1962–1964 (2001).
M. S. Brown, J. Ye, R. B. Rawson, and J. L. Goldstein, Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans, Cell 100:391–8 (2000).
S. Soriano, D. E. Kang, M. Fu, et al., Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing, J Cell Biol 152:785–94 (2001).
X. Xia, S. Qian, S. Soriano, et al., Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis, Proc Natl Acad Sci U S A 98:10863–8 (2001).
D. Hartmann, J. Toumoy, P. Saftig, W. Annaert, and B. De Strooper, Implication of APP secretases in notch signaling, J Mol Neurosci 17:171–81 (2001).
L. Bertram, D. Blacker, K. Mullin, et al., Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q, Science 290:2302–2303 (2000).
N. Ertekin-Taner, N. Graff-Radford, L. Younkin, et al., Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees, Science 290:2303–2304 (2000).
A. Myers, P. Holmans, H. Marshall, et al., Susceptibility locus for Alzheimer’s disease on chromosome 10, Science 290:2304–2305 (2000).
A. Takeuchi, M. Irizarry, K. Duff, et al., Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss, Am J Pathol 157:331–339 (2000).
J. Liu, D. W. Killilea, and B. N. Ames, Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid, Proc Natl Acad Sci U S A 99:1876–81 (2002).
G. Fiskum, A. Murphy, and M. Beal, Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases, J Cerebral Blood Flow Metab 19:351–369 (1999).
M. P. Mattson, S. L. Chan, and W. Duan, Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior, Physiol Rev 82:637–72 (2002).
D. Kuhl, E. Metter, W. Riege, and R. Hawkins, The effect of normal aging on patterns of local cerebral glucose utilization, Ann Neurol 15:S133–S137 (1984).
G. Reaven, L. Thompson, D. Nahum, and E, Haskins, Relationship between hyperglycemia and cognitive function in older NIDDM patients, Diabetes Care 13:16–21 (1990).
A. McCall, The impact of diabetes on the CNS, Diabetes 41:557–570 (1992).
G. J. Biessels, L. P. van der Heide, A. Kamal, R. L. Bleys, and W. H. Gispen, Ageing and diabetes: implications for brain function, Eur J Pharmacol 441:1–14 (2002).
J. Heitner, and D. Dickson, Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects:A retrospective postmortem immunocytochemical and histofluorescent study, Neurol 49:1306–1311 (1997).
J. Halter, Alzheimer’s disease and non-insulin-dependent diabetes mellitus: common features do not make common bedfellows, J Am Geriatr Soc 44:992–993 (1996).
C. Brayne, F. Matthews, J. Xuereb, J. Broome, a. et, and m. o. t. N. G. o. t. M. C. F. a. A. Study), Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet 357:169–175 (2001).
A. Barber, E. Lieth, S. Khin, D. Antonetti, A. Buchanan, and T. Gardner, Neural apoptosis in the retina during experimental and human diabetes:Early onset and effect of insulin, J Clin Invest 102:783–791 (1998).
L. V. Johnson, W. P. Leitner, A. J. Rivest, M. K. Staples, M. J. Radeke, and D. H. Anderson, The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration, Proc Natl Acad Sci U S A 99:11830–5 (2002).
S. Yamagishi, T. Okamoto, S. Amano, et al., Palmitate-induced apoptosis of microvascular endothelial cells and pericytes, Mol Med 8:179–84 (2002).
S. E. Vermeer, N. D. Prins, T. den Heijer, A. Hofman, P. J. Koudstaal, and M. M. Breteler, Silent brain infarcts and the risk of dementia and cognitive decline, N Engl J Med 348:1215–22 (2003).
S. Kalmijn, E. Feskens, L. Launer, T. Stijnen, and D. Kromhout, Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men, Diabetologia 38:1096–1102 (1995).
A. Ott, R. Stolk, A. Hofman, F. van Harskamp, D. Grobbee, and M. Breteler, Association of diabetes mellitus and dementia: the Rotterdam Study, Diabetologia 39:1392–1397 (1996).
J. Kuusisto, K. Koivisto, L. Mykkänen, et al., Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study, Brit Med J 315:1045–104 (1997).
C. Leibson, W. Rocca, V. Hanson, et al., Risk of dementia among persons with diabetes mellitus: a population-based cohort study, Am J Epidemiol 145:301–308 (1997).
E. Gregg, K. Yaffe, J. Cauley, et al., Is diabetes associated with cognitive impairment and cognitive decline among older women?, Arch Intern Med 160:174–180 (2000).
D. Bennett, Diabetes and change in cognitive function, Arch Intern Med 160:141–143 (2000).
E. Feskens, L. Havekes, S. Kalmijn, P. de Knijff, L. Launer, and D. Kromhout, Apolipoprotein e4 allele and cognitive decline in elderly men, Brit Med J 309:1202–1206 (1994).
G. Razay, and G. Wilcock, Hyperinsulinaemia and Alzheimer’s disease, Age Ageing 23:396–399 (1994).
S. Craft, E. Peskind, M. Schwartz, G. Schellenberg, M. Raskind, and D. Porte, Jr, Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype, Neurol 50:164–168 (1998A).
M. Haan, L. Shemanski, W. Jagust, T. Manolio, and L. Kuller, The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons, JAMA 282:40–46 (1999).
J. Molina, F. Jimenez-Jimenez, C. Vargas, et al., Cerebrospinal fluid levels of insulin in patients with Alzheimer’s disease, Acta Neurol Scand 106:347–350 (2002).
S. Kalmijn, L. Launer, A. Ott, J. Witteman, A. Hofman, and M. Breteler, Dietary fat intake and the risk of incident dementia in the Rotterdam Study, Ann Neurol 42:776–782 (1997).
A. Ott, A. Slooter, A. Hofman, et al., Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study, Lancet 351:1840–1843 (1998).
J. Orgogozo, J. Dartigues, S. Lafont, et al., Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area., Rev Neurol 153:185–192 (1997).
A. Ruitenberg, J. van Swieten, J. Witteman, et al., Alcohol consumption and risk of dementia: the Rotterdam Study, Lancet 359:281–286 (2002).
K. J. Mukamal, L. H. Kuller, A. L. Fitzpatrick, W. T. Longstreth, Jr., M. A. Mittleman, and D. S. Siscovick, Prospective study of alcohol consumption and risk of dementia in older adults, Jama 289:1405–13 (2003).
L. Refolo, M. Pappolla, B. Malester, et al., Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model, Neurobiol Dis 7:321–331 (2000).
S. Hoyer, The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update, J Neural Transm 109:341–360 (2002).
V. Grill, M. Gutniak, O. Björkman, et al., Cerebral blood flow and substrate utilization in insulin-treated diabetic subjects, Am J Physiol 258:E813–E820 (1990).
M. Gutniak, G. Blomqvist, L. Widén, S. Stone-Elander, B. Hamberger, and V. Grill, D-[U-11C]glucose uptake and metabolism in the brain of insulin-dependent diabetic subjects, Am J Physiol 258:E805–E812 (1990).
C. Fanelli, C. Dence, J. Markham, et al., Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes, Diabetes 47:1444–1450 (1998).
S. Hasselbalch, G. Knudsen, C. Videbaek, et al., No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans, Diabetes 48:1915–1921 (1999).
P. Freychet, Insulin receptors and insulin actions in the nervous system, Diabetes/Metab Res Rev 16:390–392 (2000).
C. Park, Cognitive effects of insulin in the central nervous system, Neurosci Biobehav Rev 25:311–323 (2001).
W. Zhao, H. Chen, H. Xu, et al., Brain insulin receptors and spatial memory: Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats, J Biol Chem 274:34893–34902 (1999).
A. Chaudhuri, Y. Kanjwal, P. Mohanty, et al., Insulin-induced vasodilatation of internal carotid artery, Metab Clin Exp 48:1470–1473 (1999).
L. Reagan, A. Magariños, D. Yee, et al., Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress, Brain Res 862:292–300 (2000).
S. M. Manschot, G. J. Biessels, N. E. Cameron, et al., Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats, Brain Res 966:274–82 (2003).
M. Aragno, S. Parola, E. Tamagno, et al., Oxidative derangement in rat synaptosomes induced by hyperglycaemia: restorative effect of dehydroepiandrosterone treatment, Biochem Pharmacol 60:389–395 (2000).
P. Pietrini, M. Furey, G. Alexander, et al., Association between brain functional failure and dementia severity in Alzheimer’s disease: Resting versus stimulation PET study, Am J Psych 156:470–473 (1999).
K. Meguro, X. Blaizot, Y. Kondoh, M. Le, C, J. Baron, and C. Chavoix, Neocortical and hippocampal glucose heypometabolism following neurotixic lesions of the entorhinal and perithinal cortices in the non-human primate as shown by PET: Implications for Alzheimer’s disease, Brain 122:1519–1531 (1999).
A. Kennedy, R. Frackowiak, S. Newman, et al., Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease, Neurosci Lett 186:17–20 (1995).
K. Chandrasekaran, K. Hatanpää, D. Brady, and S. Rapoport, Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer’s disease, Exp Neurol 142:80–88 (1996).
G. Small, S. Komo, A. La Rue, et al., Early detection of Alzheimer’s disease by combining apolipoprotein E and neuroimaging, Ann NY Acad Sci 802:70–78 (1996).
S. Rapoport, K. Hatanpää, D. Brady, and K. Chandrasekaran, Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease, Neurodegeneration 5:473–476 (1996).
S. Rapoport, In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer’s disease, Eur Arch Psych Clin Neurosci 249Suppl3:46–55 (1999B).
G. Chetelat, and J. C. Baron, Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging, Neuroimage 18:525–41 (2003).
G. Stoppe, H. Bruhn, P. Pouwels, W. Hänicke, and J. Frahm, Alzheimer disease: Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy, Alzheimer Dis Assoc Disorders 14:112–119 (2000).
V. Ibáñez, P. Pietrini, G. Alexander, et al., Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease, Neurology 50:1585–1593 (1998).
K. Chandrasekaran, K. Hatanpää, D. Brady, J. Stoll, and S. Rapoport, Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex, Brain Res 796:13–19 (1998).
J. Blass, and G. Gibson, The role of oxidative abnormalities in the pathophysiology of Alzheimer’s disease, Rev Neurol 147:513–525 (1991).
F. Mastrogiacomo, C. Bergeron, and S. Kish, Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease, J Neurochem 61:2007–2014 (1993).
K. Sheu, A. Cooper, K. Koike, M. Koike, J. Lindsay, and J. Blass, Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer’s disease, Ann Neurol 35:312–38 (1994).
S. Hoyer, Oxidative metabolism deficiencies in brains of patients with Alzheimer’s disease, Acta Neurol Scand Suppl 165:18–24 (1996).
G. Gibson, H. Zhang, K. Sheu, et al., Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation, Ann Neurol 44:676–681 (1998).
A. Nulton-Persson, and L. Szweda, Modulation of mitochondrial function by hydrogen peroxide, J Biol Chem 276:23357–23361 (2001).
L. Frölich, D. Blum-Degen, H. Bernstein, et al., Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease, J Neural Transmission 105:423–438 (1998).
R. Russell, 3d, and H. Taegtmeyer, Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate, J Clin Invest 87:384–390 (1991).
R. Russell, 3d, and H. Taegtmeyer, Coenzyme A sequestration in rat hearts oxidizing ketone bodies, J Clin Invest 89:968–973 (1992).
L. Tretter, and V. Adam-Vizi, Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress, J Neurosci 20:8972–8979 (2000).
V. I. Bunik, and C. Sievers, Inactivation of the 2-oxo acid dehydrogenase complexes upon generation of intrinsic radical species, Eur J Biochem 269:5004–15 (2002).
S. Kish, Brain energy metabolizing enzymes in Alzheimer’s disease: alphaketoglutarate dehydrogenase complex and cytochrome oxidase, Ann NY Acad Sci 826:218–228 (1997).
F. Mastrogiacomo, J. Lindsay, L. Bettendorff, J. Rice, and S. Kish, Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease, Ann Neurol 39:592–598 (1996).
N. Sims, Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer’s disease, Neurodegeneration 5:435–440 (1996).
J. Bolaños, A. Almeida, E. Fernández, et al., Potential mechanisms for nitric oxidemediated impairment of brain mitochondrial energy metabolism, Biochem Soc Transact 25:944–949 (1997A).
J. Bolaños, A. Almeida, V. Stewart, et al., Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases, J Neurochem 68:2227–2240 (1997B).
J. Wilson, Antioxidant defense of the brain: a role for astrocytes, Can J Physiol Pharmacol 75:1149–1163 (1997).
B. Beltrán, A. Mathur, M. Duchen, J. Erusalimsky, and S. Moncada, The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death, Proc Natl Acad Sci USA 97:14602–14607 (2000).
P. García-Nogales, A. Almeida, and J. Bolaños, Peroxynitrite protects neurons against nitric oxide-mediated apoptosis. A key role for glucose-6-phosphate dehydrogenase in neuroprotection., Journal of Biological Chemistry 278:864–874 (2003).
R. Ockner, N. Lysenko, N. Wu, and N. Bass, Hepatocyte growth inhibitors modulate mitochondrial and extramitochondrial fatty acid oxidation [Abstract], Hepatology 24:253A (1996).
M. Joaquin, J. Rosa, C. Salvado, et al., Hepatocyte growth factor and transforming growth factor beta regulate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatocyte primary cultures, Biochem J 314:235–240 (1996).
G. Thoresen, and T. Christoffersen, Transforming growth factor beta 1 increases the phosphoenolpyruvate carboxykinase mRNA level in cultured rat hepatocytes, Cell Biol Intl 18:171–175 (1994).
Y. H. Hong, H. B. Peng, V. La Fata, and J. K. Liao, Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulating factor by TGF-beta1, J Immunol 159:2418–23 (1997).
B. Herrera, A. M. Alvarez, A. Sanchez, et al., Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes, Faseb J 15:741–751 (2001B).
B. Herrera, M. Fernandez, A. M. Alvarez, et al., Activation of caspases occurs downstream from radical oxygen species production, Bcl-xL down-regulation, and early cytochrome C release in apoptosis induced by transforming growth factor beta in rat fetal hepatocytes, Hepatology 34:548–56 (2001A).
E. Masliah, G. Ho, and T. Wyss-Coray, Functional role of TGF beta in Alzheimer’s disease microvascular injury: lessons from transgenic mice, Neurochem Int 39:393–400 (2001).
A. Ruocco, O. Nicole, F. Docagne, et al., A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury, J Cereb Blood Flow Metab 19:1345–1353 (1999).
M. Packard, D. Mathew, and V. Budnik, Wnts and TGF beta in synaptogenesis: old friends signalling at new places, Nat Rev Neurosci 4:113–20 (2003).
S. Hoyer, Oxidative energy metabolism in Alzheimer brain: Studies in early-onset and late-onset cases, Molec Chem Neuropath 16:207–224 (1992).
H. Fukuyama, M. Ogawa, H. Yamauchi, et al., Altered cerebral energy metabolism in Alzheimer’s disease: a PET study, J Nucl Med 35:1–6 (1994).
S. Hasselbalch, P. Madsen, L. Hageman, et al., Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia, Am J Physiol 270:E746–51 (1996).
S. Bookheimer, M. Strojwas, M. Cohen, et al., Patterns of brain activation in people at risk for Alzheimer’s disease, N Engl J Med 343:450–456 (2000).
J. Zhou, U. Liyanage, M. Medina, et al., Presenilin 1 interaction in the brain with a novel member of the Armadillo family, Neuroreport 8:2085–2090 (1997).
G. Yu, F. Chen, G. Levesque, et al., The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin, J Biol Chem 273:16470–16475 (1998).
A. Takashima, M. Murayama, O. Murayama, et al., Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau, Proc Natl Acad Sci USA 95:9637–9641 (1998).
G. Levesque, G. Yu, M. Nishimura, et al., Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin, J Neurochem 72:999–1008 (1999).
F. Kirschenbaum, S. Hsu, B. Cordell, and J. McCarthy, Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling, J Biol Chem 276:7366–7375 (2001).
M. Murayama, S. Tanaka, J. Palacino, et al., Direct association of presenilin-1 with beta-catenin, FEBS Lett 433:73-77 (1998).
E. Planel, X. Sun, and A. Takeshima, Role of GSK-3beta in Alzheimer’s disease pathology, Drug Dev Res 56:491–510 (2002).
M. Peifer, Beta-catenin as oncogene: the smoking gun, Science 275:1752–1753 (1997).
M. Hart, R. de los Santos, I. Albert, B. Rubinfeld, and P. Polakis, Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, betacatenin and GSK3 beta, Current Biol 8:573–581 (1998).
J. Brakeman, S. Gu, X. Wang, G. Dolin, and J. Baraban, Neuronal localization of the Adenomatous polyposis coli tumor suppressor protein, Neurosci 91:661–572 (1999).
G. De Ferrari, and N. Inestrosa, Wnt signaling function in Alzheimer’s disease, Brain Res Rev 33:1–12 (2000).
A. Patapoutian, and L. Reichardt, Roles of Wnt proteins in neural development and maintenance, Curr Opin Neurobiol 10:392–399 (2000).
C. Sutherland, I. Leighton, and P. Cohen, Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling, Biochem J 296:15–19 (1993).
H. Eldar-Finkelman, and E. Krebs, Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action, Proc Natl Acad Sci USA 94:9660–9664 (1997).
P. Shepherd, D. Withers, and K. Siddle, Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling, Biochem J 333:471–490 (1998).
M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett, and S. Dedhar, Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase, Proc Natl Acad Sci USA 95:11211–11216 (1998).
J. Papkoff, and M. Aikawa, WNT-1 and HGF regulate GSK3-beta activity and betacatenin signaling in mammary epithelial cells, Biochem Biophys Res Comm 247:851–858 (1998).
N. Klöcker, P. Kermer, J. Weishaupt, M. Labes, R. Ankerhold, and M. Bähr, Brainderived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase/protein kinase B signaling, J Neurosci 20:6962–6967 (2000).
A. Vaillant, I. Mazzoni, C. Tudan, M. Boudreau, D. Kaplan, and F. Miller, Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival, J Cell Biol 146:955–966 (1999).
P. Bannasch, F. Klimek, and D. Mayer, Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone, J Bioenergetics Biomembranes 29:303–313 (1997).
D. Nehrbass, F. Klimek, and P. Bannasch, Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis, Am J Pathol 152:341–345 (1998).
B. Anderton, Alzheimer’s disease: clues from flies and worms, Curr Biol 9:R106–R109 (1999).
R. Bhat, J. Shanley, M. Correll, et al., Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration, Proc Natl Acad Sci USA 97:11074–11079 (2000).
M. Hetman, J. Cavanaugh, D. Kimelman, and Z. Xia, Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal, J Neurosci 20:2567–2574 (2000).
A. Georgakopoulos, P. Marambaud, S. Efthimiopoulos, et al., Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts, Mol Cell 4:893–902 (1999).
P. Marambaud, J. Shioi, G. Serban, et al., A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions, EMBO J 21:1948–1956 (2002).
W. Nishimura, I. Yao, J. Iida, N. Tanaka, and Y. Hata, Interaction of synaptic scaffolding molecule and Beta-catenin, J Neurosci 22:757–765 (2002).
M. Hong, and V. Lee, Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, J Biol Chem 272:19547–19553 (1997A).
J. Muñoz-Montaño, F. Moreno, J. Avila, and J. Diaz-Nido, Lithium inhibits Alzheimer’s disease-like tau protein phosphorylation in neurons, FEBS Lett 411:183–188 (1997).
B. Ryu, H. Ko, I. Jou, J. Noh, and B. Gwag, Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I, J Neurobiol 39:536–546 (1999).
L. Gasparini, W. J. Netzer, P. Greengard, and H. Xu, Does insulin dysfunction play a role in Alzheimer’s disease?, Trends Pharmacol Sci 23:288–93 (2002).
D. C. Solano, M. Sironi, C. Bonfini, S. B. Solerte, S. Govoni, and M. Racchi, Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway, Faseb J 14:1015–22 (2000).
C. J. Phiel, C. A. Wilson, V. M. Lee, and P. S. Klein, GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides, Nature 423:435–9 (2003).
G. Cheng, Z. Yu, D. Zhou, and M. P. Mattson, Phosphatidylinositol-3-kinase-Akt kinase and p42/p44 mitogen-activated protein kinases mediate neurotrophic and excitoprotective actions of a secreted form of amyloid precursor protein, Exp Neural 175:407–14 (2002).
L. Iacovelli, V. Bruno, L. Salvatore, et al., Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways, J Neurochem 82:216–23 (2002).
I. Tsujio, T. Tanaka, T. Kudo, et al., Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation, FEBS Letters 469:111–117 (2000).
A. Shanavas, and S. Papasozomenos, tau kinases in the rat heat shock model: possible implications for Alzheimer disease, Proc Natl Acad Sci USA 97:14139–14144 (2000).
X. Zhu, C. Rottkamp, H. Boux, A. Takeda, G. Perry, and M. Smith, Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease, J Neuropathol Exper Neurol 59:880–888 (2000).
M. Bennecib, C. Gong, I. Grundke-Iqbal, and K. Iqbal, Role of protein phosphatase-2A and −1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain, FEBS Lett 485:87–93 (2000).
E. Planel, K. Yasutake, S. Fujita, and K. Ishiguro, Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclindependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse, J Biol Chem 276:34298–34306 (2001).
M. Hoshi, A. Takashima, K. Noguchi, et al., Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain, Proc Natl Acad Sci USA 93:2719–2723 (1996).
S. Kang, T. Kwon, D. Kwon, and S. Do, Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit, J Biol Chem 274:13085–13090 (1999).
M. Mattson, and W. Klapper, Emerging roles for telomerase in neuronal development and apoptosis, J Neurosci Res 63:1–9 (2001).
R. Takano, S. Hisahara, K. Namikawa, H. Kiyama, H. Okano, and M. Miura, Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms, J Biol Chem 275:16360–16365 (2000).
O. Ozes, L. Mayo, J. Gustin, S. Pfeffer, L. Pfeffer, and D. Donner, NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature 401:82–85 (1999).
E. Beattie, D. Stellwagen, W. Morishita, et al., Control of synaptic strength by glial TNFalpha, Science 295:2282–2285 (2002).
A. Yamaguchi, M. Tamatani, H. Matsuzaki, et al., Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53, J Biol Chem 276:5256–5264 (2001).
D. Cross, A. Culbert, K. Chalmers, L. Facci, S. Skaper, and A. Reith, Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death, J Neurochem 77:94–102 (2001).
I. Skoog, and D. Gustafson, HRT and dementia, J Epidemiol Biostat 4:227–251 (1999).
K. Honda, H. Sawada, T. Kihara, et al., Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons, J Neurosci Res 60:321–327 (2000).
K. Yaffe, L. Lui, D. Grady, J. Cauley, J. Kramer, and S. Cummings, Cognitive decline in women in relation to non-protein-bound oestradiol concentrations, Lancet 356:708–712 (2000).
E. LeBlanc, J. Janowsky, B. Chan, and H. Nelson, Hormone replacement therapy and cognition: systematic review and meta-analysis, J Amer Med Assoc 285:1489–1499 (2001).
B. Cholerton, C. E. Gleason, L. D. Baker, and S. Asthana, Estrogen and Alzheimer’s disease: the story so far, Drugs Aging 19:405–27 (2002).
C. M. Clark, and J. H. Karlawish, Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies, Ann Intern Med 138:400–10 (2003).
M. Cordey, U. Gundimeda, R. Gopalakrishna, and C. J. Pike, Estrogen activates protein kinase C in neurons: role in neuroprotection, J Neurochem 84:1340–8 (2003).
C. Toran-Allerand, M. Singh, and G. Sétáló, Jr, Novel mechanisms of estrogen action in the brain: new players in an old story, Frontiers Neuroendocrinol 20:97–121 (1999).
R. Bi, M. Foy, R. Vouimba, R. Thompson, and M. Baudry, Cyclic changes in estradiol regulate synaptic plasticity through the MAP kinase pathway, Proc Natl Acad Sci U S A 98:13391–13395 (2001).
D. Kang, S. Soriano, M. Frosch, et al., Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer’s disease-linked PS1 mutants in the beta-catenin-signaling pathway, J Neurosci 19:4229–4237 (1999).
W. Stoothoff, C. Bailey, K. Mi, S. Lin, and G. Johnson, Axin negatively affects tau phosphorylation by glycogen synthase kinase 3-beta, Journal of Neurochemistry 83:904–913 (2002).
Z. Zhang, H. Hartmann, V. Do, et al., Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis, Nature 395:698–702 (1998).
C. Weihl, G. Ghadge, S. Kennedy, N. Hay, R. Miller, and R. Roos, Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB, J Neurosci 19:5360–5369 (1999).
M. Nishimura, G. Yu, G. Levesque, et al., Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin a component of the presenilin protein complex, Nature Med 5:164–169 (1999).
B. Passer, L. Pellegrini, P. Vito, J. Ganjei, and L. D’Adamio, Interaction of Alzheimer’s presenilin-1 and presenilin-2 with Bcl-X(L): A potential role in modulating the threshold of cell death, J Biol Chem 274:24007–24013 (1999).
J. Tan, T. Town, A. Placzek, A. Kundtz, H. Yu, and M. Mullan, Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer’s beta-amyloid 1-40 peptide in PC 12 cells, Neuroscience Letters 272:5–8 (1999).
Q. Guo, W. Fu, B. Sopher, et al., Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice, Nature Med 5:101–106 (1999).
R. Nuydens, C. Heers, A. Chadarevian, et al., Sodium butyrate induces aberrant tau phosphorylation and programmed cell death in human neuroblastoma cells, Brain Res 688:86–94 (1995).
M. Erecinska, D. Nelson, Y. Daikhin, and M. Yudkoff, Regulation of GAB A level in rat brain synaptosomes: fluxes through enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies, J Neurochem 67:2325–2334 (1996C).
M. Zhang, Y. Gong, and G. Minuk, The effects of ethanol and gamma aminobutyric acid alone and in combination on hepatic regenerative activity in the rat, Journal of Hepatology 29:638–41 (1998).
G. Minuk, R. Erlitzki, Y. Gong, and M. Zhang, Identification and characterization of GAB A A receptors and GABA transport proteins in the liver, Hepatology 30:308 A (1999).
J.-P. Roperch, V. Alvaro, S. Prieur, et al., Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression, Nature Medicine 4:835–838 (1998).
R. Ren, J. Lah, A. Diehlmann, et al., Differential effects of transforming growth factor-betaS and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes, Neurosci 93:1041–1049 (1999).
B. Wolozin, K. Iwasaki, P. Vito, et al., Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation, Science 274:1710–3 (1996).
A. Copani, F. Condorelli, A. Caruso, et al., Mitotic signaling by beta-amyloid causes neuronal death, FASEB J 13:2225–2234 (1999).
A. Giovanni, E. Keramaris, E. Morris, et al., E2F1 mediates death of B-amyloidtreated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3, J Biol Chem 275:11553–11560 (2000).
Q. Wu, C. Combs, S. Cannady, D. Geldmacher, and K. Herrup, Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons, Neurobiol Aging 21:797–806 (2000).
R. Ockner, Apoptosis and liver diseases: Recent concepts of mechanism and significance, J Gastroenterol Hepatol 16:248–260 (2001).
S. Fukumoto, T. Mutoh, T. Hasegawa, et al., GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation, J Biol Chem 275:5832–8 (2000).
A. Copani, D. Melchiorri, A. Caricasole, et al., Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons, J Neurosci 22:3963–8 (2002).
K. L. Jordan-Sciutto, L. M. Malaiyandi, and R. Bowser, Altered distribution of cell cycle transcriptional regulators during Alzheimer disease, J Neuropathol Exp Neurol 61:358–67 (2002).
Y. Yang, E. J. Mufson, and K. Herrup, Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease, J Neurosci 23:2557–63 (2003).
J. J. Pei, H. Braak, C. X. Gong, et al., Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer’s disease neurofibrillary degeneration, Acta Neuropathol (Berl) 104:369–76 (2002).
J. Dypbukt, M. Ankarcrona, M. Burkitt, et al., Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells: The role of intracellular polyamines., J Biol Chem 269:30553–30560 (1994).
A. Raina, M. Monteiro, A. McShea, and M. Smith, The role of cell cycle-mediated events in Alzheimer’s disease, Int J Exp Path 80:71–76 (1999).
J. Busser, D. Geldmacher, and K. Herrup, Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer’s disease brain, J Neurosci 18:2801–2807 (1998).
D. Liu, and L. Greene, Neuronal apoptosis at the G1/S cell cycle checkpoint, Cell Tissue Res 305:217–228 (2001).
E. Morris, E. Keramaris, H. Rideout, et al., Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage, J Neurosci 21:5017–5026 (2001).
T. Burton, B. Liang, A. Dibrov, and F. Amara, Transcriptional activation and increase in expression of Alzheimer’s beta-amyloid precursor protein gene is mediated by TGF-beta in normal human astrocytes, Biochem Biophys Res Commun 295:702–12 (2002).
T. Wyss-Coray, F. Yan, A. H. Lin, et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice, Proc Natl Acad Sci U S A 99:10837–42 (2002).
G. Halliday, S. Robinson, C. Shepherd, and J. Kril, Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms, Clin Exper Pharmacol Physiol 27:1–8 (2000).
P. McGeer, Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer’s disease, Drugs Aging 17:1–11 (2000).
T. Wyss-Coray, and L. Mucke, Ibuprofen, inflammation and Alzheimer disease, Nature Med 6:973–974 (2000).
B. in t’ Veld, A. Ruitenberg, A. Hofman, et al., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease, N Engl J Med 345:1515–1521 (2001).
P. Zandi, and J. Breitner, Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence, Neurobiol Aging 22:811–817 (2001).
S. E. Nilsson, B. Johansson, S. Takkinen, et al., Does aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged ≥80 years, Eur J Clin Pharmacol 59:313–9 (2003).
T. Thomas, T. Nadackal, and K. Thomas, Aspirin and non-steroidal antiinflammatory drugs inhibit amyloid-beta aggregation, Neuroreport 12:3263–3267 (2001).
S. Weggen, J. Eriksen, P. Das, et al., A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity, Nature 414:212–216 (2001).
T. Morihara, T. Chu, O. Ubeda, W. Beech, and G. Cole, Selective inhibition of Abeta42 production, Journal of Neurochemistry 83:1009–1012 (2002).
J. L. Eriksen, S. A. Sagi, T. E. Smith, et al., NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J Clin Invest 112:440–9 (2003).
S. A. Sagi, S. Weggen, J. Eriksen, T. E. Golde, and E. H. Koo, The noncyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production, J Biol Chem 278:31825–30 (2003).
P. S. Aisen, K. A. Schafer, M. Grundman, et al., Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA 289:2819–26 (2003).
J. Yuan, and B. Yankner, Apoptosis in the nervous system, Nature 407:802–809 (2000).
P. Klein, and D. Melton, A molecular mechanism for the effect of lithium on development, Proc Natl Acad Sci USA 93:8455–8459 (1996).
V. Stambolic, L. Ruel, and J. Woodgett, Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells, Curr Biol 6:1664–1668 (1996).
E. Chalecka-Franaszek, and D. Chuang, Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons, Proc Natl Acad Sci USA 96:8745–8750 (1999).
S. Summers, A. Kao, A. Kohn, et al., The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism, J Biol Chem 274:17934–17940 (1999).
F. Staal, B. Burgering, M. van de Wetering, and H. Clevers, Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells, Intl Immunol 11:317–323 (1999).
K. Ptashne, F. Stockdale, and S. Conlon, Initiation of DNA synthesis in mammary epithelium and mammary tumors by lithium ions, J Cellular Physiol 103:41–6 (1980).
H. Cui, Y. Meng, and R. Bulleit, Inhibition of glycogen synthase kinase 3beta activity regulates proliferation of cultured cerebellar granule cells, Brain Research Devel Brain Res 111:177–188 (1998).
G. Moore, J. Bebchuk, I. Wilds, G. Chen, and H. Menji, Lithium-induced increase in human brain grey matter, Lancet 356:1241–1242 (2000).
S. Nonaka, C. Hough, and D. Chuang, Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, Proc Natl Acad Sci USA 95:2642–2647 (1998).
F. Lucas, R. Goold, P. Gordon-Weeks, and P. Salinas, Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium, J Cell Sce 111:1351–1361 (1998).
M. Hong, D. Chen, P. Klein, and V. Lee, Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3, J Biol Chem 272:25326–25332 (1997B).
I. Blasko, M. Wagner, N. Whitaker, B. Grubeck-Loebenstein, and P. Jansen-Dürr, The amyloid beta peptide abeta (25-35) induces apoptosis independent of p53, FEBS Letters 470:221–225 (2000).
E. Paradis, H. Douillard, M. Koutroumanis, C. Goodyer, and A. LeBlanc, Amyloid beta peptide of Alzheimer’s disease downregulates Bcl-2 and upregulates bax expression in human neurons, J Neurosci 16:7533–7539 (1996).
G. Alvarez, J. Muñoz-Montaño, J. Satrústegui, J. Avila, E. Bogónez, and J. Díaz-Nido, Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration, FEBS Letters 453:260–264 (1999).
H. Wei, P. Leeds, Y. Qian, W. Wei, R.-W. Chen, and D.-M. Chuang, Beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment, Eur J Pharmacol 392:117–123 (2000).
O. Ghribi, M. M. Herman, and J. Savory, Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation, J Neurosci Res 71:853–62 (2003).
R. S. Jope, and G. N. Bijur, Mood stabilizers, glycogen synthase kinase-3beta and cell survival, Mol Psychiatry 7Suppl 1:S35–45 (2002).
J. C. Soares, Can brain-imaging studies provide a ‘mood stabilizer signature?’ Mol Psychiatry 7Suppl 1:S64–70 (2002).
S. Washizuka, C. Kakiuchi, K. Mori, et al., Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder, Am J Med Genet Part B 120B:72–8 (2003).
P. Videbech, B. Ravnkilde, T. H. Pedersen, et al., The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis, Acta Psychiatr Scand 106:35–44 (2002).
N. Jha, O. Jurma, G. Lalli, et al., Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: Implications for Parkinson’s disease, J Biol Chem 275:26096–26101 (2000).
K. Conway, J. Rochet, R. Bieganski, and P. Lansbury, Jr, Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science 294:1346–1349 (2001).
R. Sharon, M. Goldberg, I. Bar-Josef, R. Betensky, J. Shen, and D. Selkoe, alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins, Proc Natl Acad Sci U S A 98:9110–9115 (2001).
S. Prusiner, Prions, Proc Natl Acad Sci USA 95:13363–13383 (1998).
T. Voigtlander, S. Kloppel, P. Birner, et al., Marked increase of neuronal prion protein immunoreactivity in Alzheimer’s disease and human prion diseases, Acta Neuropathol (Berl) 101:417–423 (2001).
S. Mouillet-Richard, M. Ermonval, C. Chebassier, et al., Signal transduction through prion protein, Science 289:1925–1928 (2000).
C. Wu, S. Butz, Y. Ying, and R. Anderson, Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane, J Biol Chem 272:3554–3559 (1997).
H. Chapman, Y. Wei, D. Simon, and D. Waltz, Role of urokinase receptor and caveolin in regulation of integrin signaling, Thromb Haemostasis 82:291–297 (1999).
X. Sun, S. Pons, T. Asano, M. Myers, Jr, E. Glasheen, and M. White, The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation, J Biol Chem 271:10583–10587 (1996).
M. Resh, Fyn a Src family tyrosine kinase, Intl J Biochem Cell Biol 30:1159–1162 (1998).
S. Grant, T. O’Dell, K. Karl, P. Stein, P. Soriano, and E. Kandel, Impaired long-term potentiation spatial learning and hippocampal development in fyn mutant mice, Science 258:1903–1910 (1992).
C. Mastick, and A. Saltiel, Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells, J Biol Chem 272:20706–20714 (1997).
H. Beggs, S. Baragona, J. Hemperly, and P. Maness, NCAM140 interacts with the focal adhesion kinase p125(fak) and the SRC-related tyrosine kinase p59(fyn), J Biol Chem 272:8310–8319 (1997).
C. O’Donovan, D. Tobin, and T. Cotter, Prion protein fragment PrP-(106–126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells, J Biol Chem 276:43516–43523 (2001).
M. Perez, A. I. Rojo, F. Wandosell, J. Diaz-Nido, and J. Avila, Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3, Biochem J 372:129–36 (2003).
D. Pratico, Alzheimer’s disease and oxygen radicals: new insights, Biochem Pharmacol 63:563–567 (2002).
D. A. Butterfield, and C. B. Pocernich, The glutamatergic system and Alzheimer’s disease: therapeutic implications, CNS Drugs 17:641–52 (2003).
R. J. Mark, Z. Pang, J. W. Geddes, K. Uchida, and M. P. Mattson, Amyloid betapeptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation, J Neurosci 17:1046–54 (1997).
T. Prapong, J. Buss, W. Hsu, P. Heine, H. West Greenlee, and E. Uemura, Amyloid beta-peptide decreases neuronal glucose uptake despite causing increase in GLUT3 mRNA transcription and GLUT3 translocation to the plasma membrane, Exp Neurol 174:253–258 (2002).
E. Uemura, and H. Greenlee, Amyloid beta-peptide inhibits neuronal glucose uptake by preventing exocytosis, Exp Neurol 170:270–276 (2001).
I. Kaneko, N. Yamada, Y. Sakuraba, M. Kamenosono, and S. Tutumi, Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue, J Neurochem 65:2585–2593 (1995).
J. N. Keller, Z. Pang, J. W. Geddes, et al., Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal, J Neurochem 69:273–84 (1997).
L. Canevari, J. B. Clark, and T. E. Bates, beta-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria, FEBS Lett 457:131–4 (1999).
C. Rodrigues, S. Sola, M. Brito, C. Brondino, D. Brites, and J. Moura, Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate, Biochem Biophys Res Commun 281:468–474 (2001).
F. Bosetti, F. Brizzi, S. Barogi, et al., Cytochrome c oxidase and mitochondrial F(1)F(0)-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease, Neurobiol Aging 23:371–376 (2002).
C. Casley, L. Canevari, J. Land, J. Clark, and M. Sharpe, Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities, J Neurochem 80:91–100 (2002).
L. Mucke, E. Masliah, G. Q. Yu, et al., High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, J Neurosci 20:4050–8 (2000).
S. Cardoso, R. Swerdlow, and C. Oliveira, Induction of cytochrome c-mediated apoptosis by amyloid beta 25–35 requires functional mitochondria, Brain Res 931:117–125 (2002).
P. Kienlen-Campard, S. Miolet, B. Tasiaux, and J. N. Octave, Intracellular amyloidbeta 1–42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis, J Biol Chem 277:15666–70 (2002).
Y. Zhang, R. McLaughlin, C. Goodyer, and A. LeBlanc, Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons, J Cell Biol 156:519–29 (2002).
L. E. Goldstein, J. A. Muffat, R. A. Cherny, et al., Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease, Lancet 361:1258–65 (2003).
R. Kayed, E. Head, J. L. Thompson, et al., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300:486–9 (2003).
V. Fonte, V. Kapulkin, A. Taft, A. Fluet, D. Friedman, and C. D. Link, Interaction of intracellular beta amyloid peptide with chaperone proteins, Proc Natl Acad Sci U S A 99:9439–44 (2002).
G. Alvarez, M. Ramos, F. Ruiz, J. Satrustegui, and E. Bogonez, Pyruvate protection against beta-amyloid-induced neuronal death: role of mitochondrial redox state, J Neurosci Res 73:260–9 (2003).
H. Y. Wang, M. R. D’Andrea, and R. G. Nagele, Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells, Neurobiol Aging 23:213–23 (2002).
G. K. Gouras, J. Tsai, J. Naslund, et al., Intraneuronal Abeta42 accumulation in human brain, Am J Pathol 156:15–20 (2000).
L. Xie, E. Helmerhorst, K. Taddei, B. Plewright, W. Van Bronswijk, and R. Martins, Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor, J Neurosci 22:RC221–5 (2002).
M. Harris, Y. Wang, N. Pedigo, Jr, K. Hensley, D. Butterfield, and J. Carney, Amyloid beta peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures, J Neurochem 67:277–286 (1996).
Y. Ikegaya, S. Matsuura, S. Ueno, et al., Beta-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy, J Biol Chem 277:32180–6 (2002).
W. Farris, S. Mansourian, Y. Chang, et al., Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc Natl Acad Sci U S A 100:4162–7 (2003).
B. C. Miller, E. A. Eckman, K. Sambamurti, et al., Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo, Proc Natl Acad Sci U S A 100:6221–6 (2003).
D. Gabuzda, J. Busciglio, L. Chen, P. Matsudaira, and B. Yankner, Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative, J Biol Chem 269:13623–13628 (1994).
W. Meier-Ruge, and C. Bertoni-Freddari, The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer’s disease, Reviews in the Neurosciences 7:1–19 (1996).
L. Zhang, B. Zhao, D. T. Yew, J. W. Kusiak, and G. S. Roth, Processing of Alzheimer’s amyloid precursor protein during H2O2-induced apoptosis in human neuronal cells, Biochem Biophys Res Commun 235:845–8 (1997).
F. Ekinci, M. Linsley, and T. Shea, Beta-amyloid-induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation, Molec Brain Res 76:389–395 (2000).
H. Misonou, M. Morishima-Kawashima, and Y. Ihara, Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells, Biochemistry 39:6951–9 (2000).
D. Paola, C. Domenicotti, M. Nitti, et al., Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells, Biochem Biophys Research Commun 268:642–646 (2000).
E. Tamagno, P. Bardini, A. Obbili, et al., Oxidative stress increases expression and activity of BACE in NT2 neurons, Neurobiol Dis 10:279–88 (2002).
A. Volterra, D. Trotti, C. Tromba, S. Floridi, and G. Racagni, Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes, J Neurosci 14:2924–2932 (1994).
D. Trotti, D. Rossi, O. Gjesdal, et al., Peroxynitrite inhibits glutamate transporter subtypes, J Biol Chem 271:5976–5979 (1996).
Y. Chen, W. Ying, V. Simma, et al., Overexpression of Cu,Zn superoxide dismutase attenuates oxidative inhibition of astrocyte glutamate uptake, J Neurochem 75:939–945 (2000).
N. Bogdanovic, M. Zilmer, K. Zilmer, A. Rehema, and E. Karelson, The Swedish APP670/671 Alzheimer’s disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex, Dement Geriatr Cogn Disord 12:364–370 (2001 A).
Y. Huang, X. Q. Liu, T. Wyss-Coray, W. J. Brecht, D. A. Sanan, and R. W. Mahley, Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons, Proc Natl Acad Sci U S A 98:8838–43 (2001).
A. Dresner, D. Laurent, M. Marcucci, et al., Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity, J Clin Invest 103:253–259 (1999).
Z. Jiang, Y. Lin, A. Clemont, et al., Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats, J Clin Invest 104:447–457 (1999).
K. Cusi, K. Maezono, A. Osman, et al., Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle, J Clin Invest 105:311–320 (2000).
H. Steinberg, G. Paradisi, G. Hook, K. Crowder, J. Cronin, and A. Baron, Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production, Diabetes 49:1231–1238 (2000).
Y. Kruszynska, D. Worrall, J. Ofrecio, J. Frias, G. Macaraeg, and J. Olefsky, Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation, J Clin Endocrinol Metab 87:226–234 (2002).
A. Volterra, D. Trotti, P. Cassutti, et al., High sensitivity of glutamate uptake to extracellular free arachidonic acid levels in rat cortical synaptosomes and astrocytes, J Neurochem 59:600–606 (1992).
N. Ruderman, P. Ross, M. Berger, and MN. Goodman, Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats, Biochem J 138:1–10 (1974).
M. Lovell, W. Ehmann, M. Mattson, and WR. Markesbery, Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease, Neurobiol Aging 18:457–461 (1997).
L. McGrath, B. McGleenon, S. Brennan, D. McColl, S. McILroy, and A. Passmore, Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde, QJM 94:485–490 (2001).
I. Kruman, A. Bruce-Keller, D. Bredesen, G. Waeg, and M. Mattson, Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis, J Neurosci 17:5089–5100 (1997).
M. Arai, H. Yamazaki, K. Inoue, and T. Fushiki, Effects of intracranial injection of transforming growth factor-beta relevant to central fatigue on the waking electroencephalogram of rats: Comparison with effects of exercise, Prog Neuro-Psychopharmacol Biol Psych 26:307–312 (2002).
H. Yamazaki, M. Arai, S. Matsumura, K. Inoue, and T. Fushiki, Intracranial administration of transforming growth factor-beta3 increases fat oxidation in rats, Am J Physiol Endocrinol Metab 283:E536–44 (2002).
F. Lezoualc’h, Y. Sagara, F. Holsboer, and C. Behl, High constitutive NF-kappa B activity mediates resistance to oxidative stress in neuronal cells, J Neurosci 18:3224–3232 (1998).
B. Kaltschmidt, M. Uherek, H. Wellmann, B. Volk, and C. Kaltschmidt, Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis, Proc Natl Acad Sci USA 96:9409–14 (1999).
A. Beg, and D. Baltimore, An essential role for NK-kappaB in preventing TNFalpha-induced cell death, Science 274:782–784 (1996).
D. Van Antwerp, S. Martin, T. Kafri, D. Green, and I. Verma, Suppression of TNFalpha-induced apoptosis by NF-kappaB, Science 274:787–789 (1996).
C.-Y. Wang, M. Mayo, and A. Baldwin, Jr, TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB, Science 274:784–787 (1996).
C. Sen, and L. Packer, Antioxidant and redox regulation of gene transcription, FASEB J 10:709–720 (1996).
V. Lakshminarayanan, E. Drab-Weiss, and K. Roebuck, H2O2 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-1 and NF-kappaB to the interleukin-8 promoter in endothelial and epithelial cells, J Biol Chem 273:32670–32678 (1998).
E. Shaulian, and M. Karin, AP-1 as a regulator of cell life and death, Nat Cell Biol 4:E131–6 (2002).
P. Sanna, M. Cammalleri, F. Berton, et al., Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region, J Neurosci 22:3359–3365 (2002).
H. Y. Man, Q. Wang, W. Y. Lu, et al., Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons, Neuron 38:611–24 (2003).
P. Opazo, A. M. Watabe, S. G. Grant, and T. J. O’Dell, Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signalrelated kinase-independent mechanisms, J Neurosci 23:3679–88 (2003).
Q. Wang, L. Liu, L. Pei, et al., Control of synaptic strength, a novel function of Akt, Neuron 38:915–28 (2003).
L. Zhang, G. Xing, J. Barker, et al., Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway, Neurosci Lett 312:125–128 (2001).
R. Dodel, Y. Du, K. Bales, F. Gao, and S. Paul, Sodium salicylate and 17betaestradiol attenuate nuclear transcription factor NF-kappaB translocation in cultured rat astroglial cultures following exposure to amyloid A beta(1-40) and lipopolysaccharides, J Neurochem 73:1453–1460 (1999).
C. Glabe, Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease, J Mol Neurosci 17:137–145 (2001).
M. Ogawa, H. Fukuyama, Y. Ouchi, H. Yamauchi, and J. Kimura, Altered energy metabolism in Alzheimer’s disease, J Neurol Sci 139:78–82 (1996).
M. Bergman, H. Salman, Y. Beloosesky, M. Djaldetti, and H. Bessler, Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli?, Alzheimer Dis Assoc Disord 16:156–60 (2002).
D. Uberti, T. Carsana, E. Bernardi, et al., Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer’s disease patients, J Cell Sci 115:3131–8 (2002).
C. Cecchi, C. Fiorillo, S. Sorbi, et al., Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer’s patients, Free Radical Biol Med 33:1372–1379 (2002).
Y. Kitamura, T. Taniguchi, and S. Shimohama, Apoptotic cell death in neurons and glial cells: implications for Alzheimer’s disease, Jpn J Pharmacol 79:1–5 (1999).
N. Chattopadhyay, D. Singh, O. Heese, et al., Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis, J Neurosci Res 61:67–74 (2000).
M. C. Sugden, K. Bulmer, G. F. Gibbons, B. L. Knight, and M. J. Holness, Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin, Biochem J 364:361–8 (2002).
D. Slosman, C, Ludwig, S. Zerarka, et al., Brain energy metabolism in Alzheimer’s disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention, Brain Res Rev 36:230–240 (2001).
Neuroinflammation Working Group, Inflammation and Alzheimer’s disease, Neurobiol Aging 21:383–421 (2000).
A. A. Farooqui, H. C. Yang, T. A. Rosenberger, and L. A. Horrocks, Phospholipase A2 and its role in brain tissue, J Neurochem 69:889–901 (1997).
G. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. White, and B. Spiegelman, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alphaand obesity-induced insulin resistance, Science 271:665–8 (1996A).
E. Sternberg, Neural-immune interactions in health and disease, J Clin Invest 100:2641–2647 (1997).
N. Rothwell, S. Allan, and S. Toulmond, The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications, J Clin Invest 100:2648–2652 (1997).
J. Licinio, and M.-L. Wong, Pathways and mechanisms for cytokine signaling of the central nervous system, J Clin Invest 100:2941–2947 (1997).
C. Greenwood, and G. Winocur, Glucose treatment reduces memory deficits in young adult rats fed high-fat diets, Neurobiol Learning Memory 75:179–189 (2001).
R. Wing, J. Vazquez, and C. Ryan, Cognitive effects of ketogenic weight-reducing diets, Intl J Obesity Rel Metab Disord 19:811–816 (1995).
S. Su, M. Cilio, Y. Sogawa, D. Silveira, G. Holmes, and C. Stafstrom, Timing of ketogenic diet initiation in an experimental epilepsy model, Devel Brain Res 29125:131–138 (2000).
X. L. Li, S. Aou, Y. Oomura, N. Hori, K. Fukunaga, and T. Hori, Impairment of longterm potentiation and spatial memory in leptin receptor-deficient rodents, Neuroscience 113:607–15 (2002).
N. Z. Gerges, A. M. Aleisa, and K. A. Alkadhi, Impaired long-term potentiation in obese Zucker rats: possible involvement of presynaptic mechanism, Neuroscience 120:535–9 (2003).
A. Navarro, M. Sanchez Del Pino, C. Gomez, J. Peralta, and A. Boveris, Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice, Am J Physiol Regul Integr Comp Physiol 282:R985–R992 (2002).
Z. Guo, A. Ersoz, D. Butterfield, and M. Mattson, Beneficial effects of dietary restriction on cerebral cortical synaptic terminals: Preservation of glucose and glutamate transport and mitochondrial function after exposure to amyloid betapeptide, iron, and 3-nitropropionic acid, J Neurochem 75:314–320 (2000).
M. Mattson, Emerging neuroprotective strategies for Alzheimer’s disease: dietary restriction telomerase activation and stem cell therapy, Exper Gerontol 35:489–502 (2000).
Z. Radák, T. Kaneko, S. Tahara, et al., Regular exercise improves cognitive function and decreases oxidative damage in rat brain, Neurochem Intl 38:17–23 (2001).
J. A. Luchsinger, M. X. Tang, S. Shea, and R. Mayeux, Caloric intake and the risk of Alzheimer disease, Arch Neurol 59:1258–63 (2002).
D. J. Foley, and L. R. White, Dietary intake of antioxidants and risk of Alzheimer disease: food for thought, Jama 287:3261–3 (2002).
H. Jick, G. Zornberg, S. Jick, S. Seshadri, and D. Drachman, Statins and the risk of dementia, Lancet 356:1627–1631 (2000).
B. Wolozin, W. Kellman, P. Ruosseau, G. Celesia, and G. Siegel, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch Neurol 57:1439–1443 (2000).
K. Fassbender, M. Stroick, T. Bertsch, et al., Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide, Neurology 59:1257–8 (2002).
K. Fassbender, M. Simons, C. Bergmann, et al., Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc Natl Acad Sci USA 98:5856–5861 (2001).
R. L. Raffai, and K. H. Weisgraber, Cholesterol: from heart attacks to Alzheimer’s disease, J Lipid Res 44:1423–30 (2003).
A. Naidu, Q. Xu, R. Catalano, and B. Cordell, Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins, Brain Research 958:100–111 (2002).
C. Geula, C.-K. Wu, D. Saroff, A. Lorenzo, M. Yuan, and B. Yankner, Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity, Nature Med 4:827–831 (1998).
P. Cryer, M. Haymond, J. Santiago, and S. Shah, Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events, New England Journal of Medicine 295:573–7 (76).
M. Hellerstein, N. Benowitz, R. Neese, et al., Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers, Journal of Clinical Investigation 93:265–72 (1994).
K. Fattinger, D. Verotta, and N. Benowitz, Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans, J Pharmacol Exp Ther 281:1238–46 (1997).
J. Rincón, A. Krook, D. Galuska, H. Wallberg-Henriksson, and J. Zierath, Altered skeletal muscle glucose transport and blood lipid levels in habitual cigarette smokers, Clin Physiol 19:135–142 (1999).
J. Manson, U. Ajani, S. Liu, D. Nathan, and C. Hennekens, A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians, Am J Med 109:538–542 (2000).
L. Fratiglioni, and H. Wang, Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies, Behaviour Brain Res 113:117–120 (2000).
W. Kukull, The association between smoking and Alzheimer’s disease: effects of study design and bias, Biol Psych 49:194–199 (2001).
S. L. Tyas, L. R. White, H. Petrovitch, et al., Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study, Neurobiol Aging 24:589–96 (2003).
O. Forlenza, J. Spink, R. Dayanandan, B. Anderton, O. Olesen, and S. Lovestone, Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons, J Neural Transmission 107:1201–1212 (2000).
R. Garrido, A. Malecki, B. Hennig, and M. Toborek, Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons, Brain Res 861:59–68 (2000).
T. Kihara, S. Shimohama, H. Sawada, et al., alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity, J Biol Chem 276:13541–13546 (2001).
K. West, J. Brognard, A. Clark, et al., Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells, Journal of Clinical Investigation 111:81–90 (2003).
S. Fujii, and K. Sumikawa, Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus, Brain Res 894:347–353 (2001).
G. Jones, B. Sahakian, R. Levy, D. Warburton, and J. Gray, Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease, Psychopharmacol 108:485–494 (1992).
K. Ono, K. Hasegawa, M. Yamada, and H. Naiki, Nicotine breaks down preformed Alzheimer’s beta-amyloid fibrils in vitro, Biol Psychiatry 52:880–6 (2002).
Z. Z. Guan, W. F. Yu, K. R. Shan, T. Nordman, J. Olsson, and A. Nordberg, Loss of nicotinic receptors induced by beta-amyloid peptides in PC 12 cells: possible mechanism involving lipid peroxidation, J Neurosci Res 71:397–406 (2003).
D. B. Freir, and C. E. Herron, Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo, J Neurophysiol 89:2917–22 (2003).
G. Watson, and S. Craft, The role of insulin resistance in the pathogenesis of Alzheimer’s disease. Implications for treatment, CNS Drugs 17:27–45 (2003).
A. M. Palmer, Pharmacotherapy for Alzheimer’s disease: progress and prospects, Trends Pharmacol Sci 23:426–33 (2002).
R. Wilson, C. Mendes De Leon, L. Barnes, et al., Participation in cognitively stimulating activities and risk of incident Alzheimer disease, JAMA 287:742–748 (2002).
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
(2004). Pathogenesis of Alzheimer Disease: Metabolic Factors. In: Integration of Metabolism, Energetics, and Signal Transduction. Springer, Boston, MA. https://doi.org/10.1007/0-306-48529-X_15
Download citation
DOI: https://doi.org/10.1007/0-306-48529-X_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-48471-1
Online ISBN: 978-0-306-48529-9
eBook Packages: Springer Book Archive